Also known as KLOW blend · GHK-Cu + BPC-157 + TB-500 + KPV
A four-peptide repair-and-skin blend — the GLOW stack plus the anti-inflammatory tripeptide KPV.
Research refreshed
KLOW is a marketed blend that generally extends the GLOW combination (GHK-Cu, BPC-157, TB-500) with KPV, the anti-inflammatory C-terminal tripeptide of α-MSH. The added KPV supplies an anti-inflammatory component alongside the repair and skin peptides. Composition and ratios are vendor-defined and not standardized; the blend has no combined clinical data, and each component is a research compound profiled on its own page.
KLOW is usually described as GLOW with KPV added — four peptides chosen to cover angiogenesis (BPC-157), cell migration (TB-500), skin and collagen (GHK-Cu), and inflammation (KPV) in a single vial. It is one of the more complex pre-mixed research blends on the market.
The more components a blend has, the more its combined behavior — stability, compatibility in one solution, and net effect — departs from anything that has been studied. No controlled trial has tested KLOW, vendor recipes differ, and none of the four components is FDA-approved. This is a research reference only.
Adds KPV (NF-κB-pathway anti-inflammatory signaling) to GHK-Cu (collagen/matrix), BPC-157 (angiogenesis), and TB-500 (cell migration). The four-way combination is a proposed convenience stack, not a studied formulation.
Behind every vial of KLOW is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how KLOW, specifically, is brought into being.
KLOW begins not as a powder but as a specification. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
KLOW is assembled by solid-phase peptide synthesis — the chain grows one protected residue at a time on resin, and what you fail to build cleanly here you pay to remove later.
The crude mixture — KLOW plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.
A real batch of KLOW proves itself: identity confirmed by mass spectrometry, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of KLOW — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
A four-component physical mixture — GHK-Cu, BPC-157, TB-500, and KPV — each synthesized and purified separately, so no single synthesis and no single purity number exist. A genuine certificate assays all four on their own, states the amount of each, and confirms copper content for the GHK-Cu portion. With four peptides in one solution, compatibility and stability are largely uncharacterized, and vendor recipes are not standardized.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Generally GHK-Cu, BPC-157, TB-500, and KPV — the GLOW three-peptide blend plus the anti-inflammatory tripeptide KPV. Exact composition is vendor-defined.
KLOW adds a fourth component, KPV, to the GLOW stack to bring in an anti-inflammatory element. Vendor formulas vary.
No controlled study has tested the mixture. Evidence exists only for the individual components, mostly in preclinical work.
No — none of the components is FDA-approved and the blend is not either. This page is a research and educational reference.
KLOW is a blend. Each component is a single compound with its own catalog monograph — purity, mechanism, and research are documented per component below.
Endogenous copper-binding tripeptide widely studied in skin and hair biology.
ViewSynthetic gastric pentadecapeptide investigated for tendon, ligament, and GI repair.
ViewThe seven-residue actin motif of thymosin β4 (LKKTETQ) — the fragment sold as a stand-in for the full 43-residue protein.
ViewAnti-inflammatory C-terminal tripeptide of α-MSH.
ViewA 43-residue actin buffer. It holds G-actin so cells can move, and its first four residues become the anti-fibrotic peptide Ac-SDKP.
ViewA 27-residue single-chain relaxin-2 analog and selective RXFP1 agonist — a simplified relaxin mimetic studied for anti-fibrotic effects.
ViewCopper-binding tripeptide (Ala-His-Lys) studied for hair-follicle stimulation and dermal repair.
ViewDosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.